Sources: London-based Isomorphic Labs, an AI drug discovery startup spun out of Google DeepMind, is in early talks to raise funds at a $40B to $50B valuation
Isomorphic Labs, an AI-powered drug discovery startup spun out of Alphabet Inc.'s Google DeepMind, is in early talks to raise new funds …
Context & Ripple Effects
Isomorphic Labs had already moved from a 2024 drug-discovery partnership with Eli Lilly and Novartis to a $2.1 billion financing led by Thrive in May 2026, following its $600 million first round in 2025. The reported new discussions test whether investors will assign a $40 billion-plus value to that research-and-partnership model.
The company remains tied to Google DeepMind, while its pharmaceutical collaborations provide the commercial setting for a financing story otherwise centered on AI research capability.
First-order effects
- Early financing talks give Isomorphic Labs and prospective investors a proposed $40 billion-plus valuation benchmark; no funding round or valuation is final until an agreement is reached.
- A valuation at that level would strengthen Isomorphic Labs' ability to finance a long drug-discovery development cycle without relying solely on milestone payments from partners such as Eli Lilly and Novartis.
Second-order effects
- Eli Lilly and Novartis gain a better-capitalized AI-discovery counterpart, while prospective investors must judge Isomorphic Labs against the funding already committed in its May round.
- The proposed price raises the evidentiary bar for other AI drug-discovery companies seeking large private rounds: investors will compare research access, pharmaceutical partnerships and funding capacity rather than AI claims alone.
Third-order effects
- If investors sustain such valuations, AI drug discovery will increasingly be financed as a concentrated frontier-lab category, with capital flowing to companies that combine model-development pedigrees with drug-company distribution.
- That structure may leave smaller discovery startups competing for partnerships and capital against a limited group of heavily funded platforms linked to major AI labs.
The trend: AI drug discovery is moving toward frontier-lab capital concentration, as investors place larger bets on companies pairing advanced AI research with pharmaceutical partnerships.